EGFR and neoplasm: Similarly, in a breast xenograft tumor model, it was found that PD-L1 glycosylation mediated by the EGFR/B3GNT3 pathway suppresses the autophagic degradation of PD-L1, and in turn, promotes tumor immune escape [148].